ClinicalTrials.Veeva

Menu
S

Star Vision Research | Burleson, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Axitinib
EYP-1901
Aflibercept
Tarcocimab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 4 total trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (...

Enrolling
Wet Age-related Macular Degeneration
Drug: Tarcocimab tedromer
Drug: Aflibercept

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.

Active, not recruiting
Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration

Enrolling
Neovascular Age-related Macular Degeneration
Drug: OTX-TKI
Drug: Aflibercept

Trial sponsors

Kodiak Sciences logo
E
Ocular Therapeutix logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems